Navigation Links
Relmada Therapeutics to Participate in BIO CEO and Investor Conference
Date:2/13/2017

NEW YORK, Feb. 13, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the company will participate in the BIO CEO and Investor Conference to be held February 13-14, 2017 at the Waldorf Astoria in New York City.

Sergio Traversa, chief executive officer of Relmada, is scheduled to present on Tuesday, February 14th at 10:30am ET in the Conrad presentation room.

Continue Reading
Sergio Traversa, CEO of Relmada Therapeutics
Sergio Traversa, CEO of Relmada Therapeutics

The BIO CEO and Investor Conference is focused on established and emerging publicly traded and select private biotech companies. For more information, visit https://www.bio.org/events/bio-ceo-investor-conference.

A live webcast of the presentation will be available through the Company's website at www.relmada.com. Please register at least 10 minutes prior to the start of the presentation to ensure timely access. The webcast and presentation will also be archived on the website for 90 days after the conference.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. The Company has a diversified portfolio of four products at various stages of development, including d-Methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist for depression and neuropathic pain; LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; oral buprenorphine (BuTab, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and topical mepivacaine (MepiGel, REL-1021), an orphan drug designated topical formulation of the local anesthetic mepivacaine. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products to address areas of high unmet medical needs. For more information, please visit Relmada's website at: www.relmada.com.  

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. We may from time to time make written or oral statements in this letter, the proxy statements filed with the SEC communications to stockholders and press releases which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based upon management's current expectations, estimates, assumptions and beliefs concerning future events and conditions and may discuss, among other things, anticipated future performance, expected product development, product potential, future business plans and costs. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list.

Contact

Investor Contact:
Michael Becker, Chief Financial Officer
Relmada Therapeutics Inc.
Tel: 646-677-3857
mbecker@relmada.com

Media Contact:
Lynn Granito
Berry & Company Public Relations
Tel: 212-253-8881
lgranito@berrypr.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/relmada-therapeutics-to-participate-in-bio-ceo-and-investor-conference-300406088.html


'/>"/>
SOURCE Relmada Therapeutics, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
2. Relmada Therapeutics Announces Results of Annual Shareholders Meeting
3. Edison Initiates Coverage on Relmada Therapeutics
4. Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
5. Relmada Therapeutics to Provide an Update on the Development Plan for LevoCap ER
6. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
7. Novira Therapeutics Completes $25 Million Series A Financing
8. Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
9. Aratana Therapeutics Adds To Drug Development Team
10. Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
11. Galectin Therapeutics: Turning Atlanta into Americas Next Silicon Valley
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2020)... ... February 18, 2020 , ... ... the launch of a new and unified global brand identity, as it celebrates ... complex engineering challenges, as well as an enthusiasm for designing and manufacturing state-of-the-art ...
(Date:2/11/2020)... BOSTON (PRWEB) , ... February ... ... privately-owned company) is pleased to announce the successful results from a long-term ... stenosis using the Inspan interspinous fixation device (INSPAN LLC). Unlike extension block ...
(Date:2/5/2020)... ... February 04, 2020 , ... Shoreline Biome ... to the strain level, has announced a new distribution partnership in Asia. , ... other products to companies and research organizations in China, Hong Kong, and Macau. ...
(Date:2/3/2020)... ... February 03, 2020 , ... Global molecular diagnostics ... OmniType, the 11-locus, single tube multiplex successor to Holotype HLA is available through ... locus-multiplexing and short library preparation, for HLA genotyping from sample to answer in ...
Breaking Biology Technology:
(Date:1/29/2020)... ... January 29, 2020 , ... Jason Burke has joined CREO, ... providing consulting services for strategy, research and development and data governance to healthcare ... Managing Partner of CREO, an innovative management consulting and advisory firm based in ...
(Date:1/28/2020)... ... January 28, 2020 , ... ... care efficiency, reduce total cost of care, and limit the utilization of high-cost ... provider group headquartered in San Antonio, Texas specializes in improving care delivery for ...
(Date:1/24/2020)... ... , ... The Rockies Venture Club and Colorado BioScience Association ... companies in the state. , “Colorado has a world-class life sciences ... to innovate and grow. This program will mobilize capital within the state ...
Breaking Biology News(10 mins):